Legend Capital returned to reinvest in a $34.4m round for pathogen testing services provider Genskey, lifting its total funding above $55m.
China-based genetic testing services provider Genskey has collected RMB230m ($34.4m) in a series C round backed by Legend Capital, the venture capital firm formed by conglomerate Legend Holdings, DealStreetAsia reported yesterday.
Private equity fund Huagai Capital led the round, which was filled out by Apricot Capital and YuanBio Venture Capital.
Genskey provides next-generation sequencing services to detect disease pathogens such as covid-19 on behalf of research labs and healthcare providers. Its services are billed as being sensitive enough to identify…
